S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
The 3-Stock Retirement Blueprint (Ad)
This Is A Memorable Time To Buy Into Micron Technology
How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
The 3-Stock Retirement Blueprint (Ad)
Let Paychex Stock Work Hard For You 
Global stocks mixed after Eurozone inflation rises
The 3-Stock Retirement Blueprint (Ad)
Declining Profits Challenge the CarMax Value Proposition
How major US stock indexes fared Friday 9/30/2022
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
The 3-Stock Retirement Blueprint (Ad)
This Is A Memorable Time To Buy Into Micron Technology
How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
The 3-Stock Retirement Blueprint (Ad)
Let Paychex Stock Work Hard For You 
Global stocks mixed after Eurozone inflation rises
The 3-Stock Retirement Blueprint (Ad)
Declining Profits Challenge the CarMax Value Proposition
How major US stock indexes fared Friday 9/30/2022
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
The 3-Stock Retirement Blueprint (Ad)
This Is A Memorable Time To Buy Into Micron Technology
How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
The 3-Stock Retirement Blueprint (Ad)
Let Paychex Stock Work Hard For You 
Global stocks mixed after Eurozone inflation rises
The 3-Stock Retirement Blueprint (Ad)
Declining Profits Challenge the CarMax Value Proposition
How major US stock indexes fared Friday 9/30/2022
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
As a Black Woman in Business for 2 Decades, Here's How I've Learned to Navigate Microaggressions and Racism in Networking
The 3-Stock Retirement Blueprint (Ad)
This Is A Memorable Time To Buy Into Micron Technology
How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
The 3-Stock Retirement Blueprint (Ad)
Let Paychex Stock Work Hard For You 
Global stocks mixed after Eurozone inflation rises
The 3-Stock Retirement Blueprint (Ad)
Declining Profits Challenge the CarMax Value Proposition
How major US stock indexes fared Friday 9/30/2022
NYSE:MDT

Medtronic - MDT Stock Forecast, Price & News

$80.75
-1.52 (-1.85%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$80.69
$83.55
50-Day Range
$80.75
$95.31
52-Week Range
$80.39
$128.85
Volume
5.94 million shs
Average Volume
6.09 million shs
Market Capitalization
$107.33 billion
P/E Ratio
20.87
Dividend Yield
3.31%
Price Target
$111.52

Medtronic MarketRank™ Forecast

Analyst Rating
Hold
2.32 Rating Score
Upside/​Downside
38.1% Upside
$111.52 Price Target
Short Interest
Healthy
0.60% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.59mentions of Medtronic in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.42%
From $5.53 to $5.83 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.36 out of 5 stars

Medical Sector

4th out of 1,093 stocks

Electromedical Equipment Industry

1st out of 23 stocks

MDT stock logo

About Medtronic (NYSE:MDT) Stock

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Receive MDT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medtronic and its competitors with MarketBeat's FREE daily newsletter.

MDT Stock News Headlines

Is This Medical Gear Maker Ready To Continue Its Rally? (MDT)
Medical gear maker Axonics rallied to a new high after an announcement that it entered the Canadian market. Is it set for bigger gains on strong revenue growth?
MarketBeat: Week in Review 8/29 – 9/2 (MDT)
The August jobs show there’s still a lot of uncertainty in the market. As you recharge this weekend, here are some of the top MarketBeat stories to focus on
Is Medtronic plc (MDT) A Good Long-Term Investment?
Medtronic (MDT) Stock Moves -0.39%: What You Should Know
Medtronic (NYSE:MDT) Reaches New 1-Year Low at $83.30
Is Trending Stock Medtronic PLC (MDT) a Buy Now?
See More Headlines
Receive MDT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medtronic and its competitors with MarketBeat's FREE daily newsletter.

MDT Company Calendar

Ex-Dividend for 7/15 Dividend
6/23/2022
Dividend Payable
7/15/2022
Last Earnings
8/23/2022
Ex-Dividend for 10/14 Dividend
9/22/2022
Today
9/30/2022
Dividend Payable
10/14/2022
Next Earnings (Estimated)
11/22/2022
Fiscal Year End
4/30/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
58505510
Employees
95,000
Year Founded
1949

Price Target and Rating

Average Stock Price Forecast
$111.52
High Stock Price Forecast
$136.00
Low Stock Price Forecast
$85.00
Forecasted Upside/Downside
+38.1%
Consensus Rating
Hold
Rating Score (0-4)
2.32
Research Coverage
19 Analysts

Profitability

Net Income
$5.04 billion
Pretax Margin
18.44%

Debt

Sales & Book Value

Annual Sales
$31.69 billion
Cash Flow
$7.44 per share
Book Value
$39.76 per share

Miscellaneous

Outstanding Shares
1,329,153,000
Free Float
1,325,298,000
Market Cap
$107.33 billion
Optionable
Optionable
Beta
0.75

Social Links


Key Executives

  • Mr. Geoffrey Straub Martha (Age 52)
    Chairman & CEO
    Comp: $4.35M
  • Ms. Karen L. ParkhillMs. Karen L. Parkhill (Age 57)
    EVP, CFO, IT & Enterprise Excellence
    Comp: $2.41M
  • Mr. Ivan K. Fong (Age 61)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $985.57k
  • Mr. Robert J. W. ten Hoedt (Age 62)
    Exec. VP and Pres, Europe, Middle East, Africa Region & Asia Pacific
    Comp: $2.02M
  • Mr. Robert John WhiteMr. Robert John White (Age 59)
    Exec. VP & Pres of Medical Surgical Portfolio
    Comp: $2M
  • Mr. Mark Ploof
    Sr. VP of Global Operations and Bus. Services
  • Ms. Jennifer M. Kirk (Age 47)
    Principal Accounting Officer, Global Controller & Chief Accounting Officer
  • Dr. Laura Mauri M.D.
    M.Sc., Sr. VP and Chief Scientific, Medical & Regulatory Officer
  • Mr. Sean Lennon
    Chief Information Officer
  • Mr. Ryan Weispfenning
    VP of Investor Relations













MDT Stock - Frequently Asked Questions

Should I buy or sell Medtronic stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MDT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDT, but not buy additional shares or sell existing shares.
View MDT analyst ratings
or view top-rated stocks.

What is Medtronic's stock price forecast for 2022?

19 analysts have issued twelve-month target prices for Medtronic's stock. Their MDT share price forecasts range from $85.00 to $136.00. On average, they anticipate the company's share price to reach $111.52 in the next twelve months. This suggests a possible upside of 38.1% from the stock's current price.
View analysts price targets for MDT
or view top-rated stocks among Wall Street analysts.

How have MDT shares performed in 2022?

Medtronic's stock was trading at $103.45 at the beginning of the year. Since then, MDT stock has decreased by 21.9% and is now trading at $80.75.
View the best growth stocks for 2022 here
.

Are investors shorting Medtronic?

Medtronic saw a decline in short interest in September. As of September 15th, there was short interest totaling 7,920,000 shares, a decline of 16.0% from the August 31st total of 9,430,000 shares. Based on an average daily volume of 5,510,000 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.6% of the company's stock are sold short.
View Medtronic's Short Interest
.

When is Medtronic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 22nd 2022.
View our MDT earnings forecast
.

How were Medtronic's earnings last quarter?

Medtronic plc (NYSE:MDT) announced its quarterly earnings data on Tuesday, August, 23rd. The medical technology company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.01. The medical technology company had revenue of $7.37 billion for the quarter, compared to analysts' expectations of $7.20 billion. Medtronic had a net margin of 16.75% and a trailing twelve-month return on equity of 13.64%. During the same period in the prior year, the company posted $1.41 EPS.
Read the conference call transcript
.

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic announced a quarterly dividend on Thursday, August 18th. Investors of record on Friday, September 23rd will be paid a dividend of $0.68 per share on Friday, October 14th. This represents a $2.72 annualized dividend and a yield of 3.37%. The ex-dividend date is Thursday, September 22nd.
Read our dividend analysis for MDT
.

Is Medtronic a good dividend stock?

Medtronic (NYSE:MDT) pays an annual dividend of $2.72 per share and currently has a dividend yield of 3.31%. The company has been increasing its dividend for 45 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 70.28%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MDT will have a dividend payout ratio of 46.66% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MDT.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic issued an update on its FY 2023 earnings guidance on Tuesday, September, 20th. The company provided earnings per share (EPS) guidance of $5.53-$5.65 for the period, compared to the consensus estimate of $5.56. The company issued revenue guidance of -.

What is Omar S. Ishrak's approval rating as Medtronic's CEO?

1,925 employees have rated Medtronic Chief Executive Officer Omar S. Ishrak on Glassdoor.com. Omar S. Ishrak has an approval rating of 92% among the company's employees. This puts Omar S. Ishrak in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medtronic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS), Home Depot (HD) and Walmart (WMT).

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How do I buy shares of Medtronic?

Shares of MDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $80.75.

How much money does Medtronic make?

Medtronic (NYSE:MDT) has a market capitalization of $107.33 billion and generates $31.69 billion in revenue each year. The medical technology company earns $5.04 billion in net income (profit) each year or $3.87 on an earnings per share basis.

How many employees does Medtronic have?

The company employs 95,000 workers across the globe.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The official website for the company is www.medtronic.com. The medical technology company can be reached via phone at (531) 438-1700, via email at investor.relations@medtronic.com, or via fax at 763-514-4879.

This page (NYSE:MDT) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.